Biomarkers, CDx & Precision Medicine US 2026
Meet Us at Booth #23 During Biomarkers, CDx & Precision Medicine US 2026
September 23-24, 2026
Gaylord Pacific Resort & Convention Center,
San Diego, CA
Join our Seer Solution Provider Presentation:
Discovery to the Clinic: The Journey from LCMS Proteomics Biomarker Discovery to a Clinical Test for Early Lung Cancer Detection
Presenter: Bruce Wilcox, PhD., CTO, PrognomiQ
A multi-omics discovery study (MOSAIC) identified protein biomarkers for early lung cancer detection, translated across 3 cohorts into a validated, protein-based LDT with strong Stage I sensitivity—now deployed with two health system partners.
Date: September 24
Time: 9:35–10:00 AM PST
Track: 1
Bruce E. Wilcox, Ph.D., is Chief Technology Officer at PrognomiQ. After earning his Ph.D. from the University of New Mexico and completing a postdoc at the National High Magnetic Field Laboratory, Dr. Wilcox built his career at the intersection of novel mass spectrometry instrumentation and large-scale plasma proteomics, driving the development of multiple commercial clinical tests. At PrognomiQ, he leads a team that has built a comprehensive multi-omics discovery platform—spanning genomics, transcriptomics, metabolomics, and proteomics—to identify and translate blood-based biomarkers into clinical use, including for early lung cancer detection.
